doi: 10.1046/j.1365-2265.1998.00403.x 7 ColaoASarnoADCappabiancaPBrigantiFPivonelloRSommaCDet al
To view or add a comment, sign in Decoding VCT220 (CX11, gimaglipron): China's Oral GLP-1 Contender Alongside Orforglipron and HRS-7535 Following positive Phase 3 topline results in Chinese adults with obesity, VCT220 (Gimaglipron, CX11), discovered by Vincentage Pharma and now being developed globally by CORXEL Pharmaceuticals, has emerged as one of China's leading oral small-molecule GLP-1 receptor agonists, with NDA submission planned for obesity and potential expansion into type 2 diabetes
Maintenance of results : To maintain a rejuvenated look, regular treatments are recommended
Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani M-R, Hosseini S-M-R, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi S-M-H, Moghadam M, Gharibi F, Mirshafiee O:, Akhondzadeh S: N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study
.png)
